Trial Profile
A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD-P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC-PG).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel
- Indications Ductal carcinoma; Early breast cancer
- Focus Therapeutic Use
- 28 Nov 2016 Status changed from active, no longer recruiting to completed.
- 28 Nov 2016 Status changed from active, no longer recruiting to completed.
- 08 Jun 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016.